title: Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
abstract: BACKGROUND
  Prostatic-specific antigen (PSA), a tumor marker helpful in the diagnosis and follow-up of prostate cancer, may rise due to causes such as prostatitis, chronic benign prostatic hyperplasia (BHP), etc. The aim of this study was to investigate the relationship between prostatitis and the level of total and free prostate-specific antigen in patients with no clinical evidence of prostate cancer.
  
  
  METHODS
  A comprehensive urological examination was performed on 156 patients aged 35-61 years old. All patients have symptoms of prostatitis. Prostate fluid culture was preformed. All patients underwent a course of antibacterial treatment after which the levels of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA) were evaluated.
  
  
  RESULTS
  An increase in TPSA (> 4 ng/ml) was observed in 14/24 (58.3%) patients with acute prostatitis and in 7/45 (15.5%) and 4/44 (9.1%) in patients with chronic bacterial prostatitis (CBP) and a bacterial prostatitis, respectively. Low blood concentration of TPSA and FPSA were observed after effective antibacterial and anti-inflammatory treatment therapy in most cases.
  
  
  CONCLUSIONS
  These data suggested that prostatitis must be considered when interpretation of TPSA and FPSA values as tumor marker.
authors.affiliation: Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Hashemite University, P.O. Box 150459, Zarqa, 13115, Jordan. nizar@hu.edu.jc
authors.forename: Mohammed Nizar G
authors.initials: MN
authors.lastname: Battikhi
authors.forename: Hussein
authors.initials: H
authors.lastname: Ismail
authors.forename: Qusey
authors.initials: Q
authors.lastname: Battikhi
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000627:therapeutic use; D004008:Diclofenac / Q000627:therapeutic use; D004756:Enterobacteriaceae Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006069:Gonorrhea / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011469:Prostatic Diseases / Q000097:blood* / Q000188:drug therapy / Q000382:microbiology; D011552:Pseudomonas Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy
chemical_list: D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004008:Diclofenac; D002939:Ciprofloxacin; D017430:Prostate-Specific Antigen